Sandra Jonsson joins Nordic Nanovector

Thursday 13 January 2022
Nordic Nanovector ASA
Appointee name
Sandra Jonsson


Sandra Jonsson, a chemist and pharmaceutical executive, has joined Nordic Nanovector ASA as chief operating officer to help it advance therapies for haematological cancers and immune diseases. She joins from Alexion Pharmaceuticals, now part of AstraZeneca Plc, where she directed commercial strategy. Prior to this, she headed commercial strategy and operations for Europe at Shire, now part of Takeda Pharmaceutical Co Ltd. Dr Jonsson received an MBA from the University of St Gallen in Switzerland, a PhD in organic chemistry from Stockholm University and an MS in chemistry and law from Uppsala University, both in Sweden.

Nordic Nanovector announced the appointment on 16 December 2021.

Copyright 2022 Evernow Publishing Ltd